Roflumilast

被引：46

作者：

Fabbri, Leonardo M. ^{[1
]}

Beghe, Bianca ^{[1
]}

Yasothan, Uma ^{[2
]}

Kirkpatrick, Peter

机构：

[1] Univ Modena & Reggio Emilia, Dipartimento Oncol Ematol & Malattie Resp, Clin Malattie Apparat Resp, Policlin Modena, I-41124 Modena, Italy

[2] IMS Hlth, London NW1 6JB, England

来源：

NATURE REVIEWS DRUG DISCOVERY | 2010年 / 9卷 / 10期

关键词：

OBSTRUCTIVE PULMONARY-DISEASE; PDE4 INHIBITOR ROFLUMILAST; COPD;

D O I：

10.1038/nrd3276

中图分类号：

Q81 [生物工程学（生物技术）]; Q93 [微生物学];

学科分类号：

071005 ; 0836 ; 090102 ; 100705 ;

摘要：

In July 2010, roflumilast (Daxas; Nycomed) was granted marketing authorization by the European Commission for the maintenance treatment of severe chronic obstructive pulmonary disease, as an add-on to bronchodilator treatment.

引用

页码：761 / 762

页数：2